Search filters

Filters
Clear All

Phase

  • 182
  • 151
  • 2
  • 188
  • 147
  • 17
  • 372
  • 1194
  • 567
  • 28
  • 43
  • 2
  • 1127
  • 1195
  • 5

Found 1200 All Conditions trials

A listing of All Conditions medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

 Evaluation of Vascular Health Profile in Predicting Venous Thromboembolism
1 years - 99 years
All genders
The main goal of this study is to utilize previously validated cytometric markers of to identify cancer patients at high risk of VTE. The primary outcome will be DVT or pulmonary embolism (PE). Patients with pancreatic and brain cancer will be enrolled as these patients are known to have higher …
 The Cancer of the Pancreas Screening-5
1 years - 99 years
All genders
The specific Aims of CAPS5 will be: Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls. Aim #2: To compare the prevalence of pancreatic fluid mutations and …
 Mild Hypofractionation using Proton Therapy or IMRT for Low- and Intermediate-Risk Prostate Cancer
99 years or below
All genders
This is a study to first establish feasibility of the study and then to register the treatment data of adult patients with a diagnosis of low or intermediate risk of prostate cancer presenting for definitive radiation treatment with either proton radiotherapy or IMRT. We propose to employ a hypofractionated strategy …
 Intratumoral Gene Mediated Cytotoxic Immunotherapy (GMCI) For Resectable Non-Small Cell Lung Cancer
99 years or below
All genders
Phase 1
Surgery is the best treatment for patients with Stage I or II lung cancer; however, nearly 60% of patients have recurrence. Additional immunotherapeutic agents given before surgery may be greatly reduce recurrence. This is a Standard Phase I, 3+3 dose escalation trial designed to evaluate the safety and toxicity of …
 KCP-330-020
18 years - 99 years
All genders
Phase 2
The purpose of this study is to see if the investigational drug, selinexor, has any effects in eligible participants with advanced unresectable dedifferentiated liposarcoma (DDLS). Selinexor will be given at a fixed oral dose of 60mg or placebo twice weekly on Days 1 and 3 during Weeks 1-6 of each …
 Cerebrovascular reactivity assessed with functional near-infrared spectroscopy as a biomarker of traumatic microvascular injury after traumatic brain injury
99 years or below
All genders
Traumatic cerebrovascular injury (TCVI) is common after traumatic brain injury (TBI) and an attractive target for therapeutic intervention. We will longitudinally measure cerebrovascular reactivity (CVR) by functional near-infrared spectroscopy (fNIRS) in acute (3 days from injury), subacute, and chronic phases after TBI as a biomarker of TCVI as compared to …
 A Phase 1b  Multicenter  Open-Label  Safety  Tolerability  and Activity Study of SYNT001 in Subjects with Chronic  Stable Warm Autoimmune Hemolytic Anemia (WAIHA)
99 years or below
All genders
Phase 1
WAIHA is caused by antibodies (proteins) that attach to red blood cells and causes their destruction. This causes anemia, which means the red blood cell count in the body becomes low. This medical research study is being done to find out more information about the investigational drug SYNT001 for the …
 UPCC 31216: Phase I/II Trial of Regorafenib  Hydroxychloroquine  and Entinostat in Metastatic Colorectal Cancer
99 years or below
All genders
Phase 2
The main purpose of this study is to find the best dose of hydroxychloroquine (HCQ) when given in combination with regorafenib and entinostat.
 UPCC 35217: A Phase 1B/2  Open label study of Niraparib plus either Ipilimumab or Nivolumab in patients with advanced Pancreatic Cancer who have achieved stability on platinum- based therapy
99 years or below
All genders
Phase 2
The main purpose of this study is to look at the effectiveness, safety, and anti-tumor activity (preventing growth of the tumor) of the drugs niraparib with either ipilimumab or nivolumab on patients and their pancreatic cancer.